John L Hays Selected Research

John L Hays Research Topics

Disease

17	Neoplasms (Cancer) 01/2024 - 03/2008
8	Ovarian Neoplasms (Ovarian Cancer) 07/2023 - 05/2013
4	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 01/2016
2	Diarrhea 07/2022 - 12/2020
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 09/2021 - 10/2013
2	Ovarian Epithelial Carcinoma 01/2021 - 01/2018
2	Fatigue 12/2020 - 05/2013
2	Liposarcoma 10/2019 - 01/2019
2	Neutropenia 04/2019 - 05/2013
2	Thrombocytopenia (Thrombopenia) 04/2019 - 10/2017
2	Neoplasm Metastasis (Metastasis) 01/2019 - 11/2018
2	Carcinogenesis 05/2018 - 01/2018
2	Hypersensitivity (Allergy) 01/2017 - 05/2013
1	Cancer Pain 01/2024
1	Adenocarcinoma 07/2022
1	Vomiting 12/2020
1	Nausea 12/2020
1	Mucositis 12/2020
1	Infections 04/2019
1	Carcinoma (Carcinomatosis) 04/2019
1	Cholangiocarcinoma 01/2019
1	Lymphatic Metastasis 01/2019
1	Melanoma (Melanoma, Malignant) 05/2018
1	Hyponatremia 10/2017
1	Triple Negative Breast Neoplasms 10/2017
1	Breast Neoplasms (Breast Cancer) 01/2017
1	Peritoneal Neoplasms 01/2017
1	Disease Progression 01/2016
1	Pancreatitis 05/2013
1	Dehydration (Water Stress) 05/2013
1	Weight Loss (Weight Reduction) 05/2013
1	Hypoalbuminemia 05/2013
1	Obesity 04/2013

Drug/Important Bio-Agent (IBA)

8	Biomarkers (Surrogate Marker)IBA 04/2022 - 06/2014
4	olaparibIBA 04/2019 - 06/2014
3	PlatinumIBA 07/2023 - 01/2017
3	Proteins (Proteins, Gene)FDA Link 12/2020 - 01/2017
3	Carboplatin (JM8)FDA LinkGeneric 04/2019 - 06/2014
2	Phosphotransferases (Kinase)IBA 10/2020 - 05/2018
2	Messenger RNA (mRNA)IBA 01/2019 - 01/2017
2	DNA (Deoxyribonucleic Acid)IBA 08/2018 - 10/2013
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2017 - 01/2016
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2015 - 10/2013
1	ORALIT (ORS)IBA 01/2024
1	pembrolizumabIBA 07/2023
1	CannabidiolIBA 01/2023
1	napabucasinIBA 07/2022
1	Paclitaxel (Taxol)FDA LinkGeneric 07/2022
1	Reactive Oxygen Species (Oxygen Radicals)IBA 07/2022
1	balstilimabIBA 09/2021
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2021
1	4- (2,6- dichlorobenzoylamino)- 1H- pyrazole- 3- carboxylic acid piperidin-4-ylamideIBA 12/2020
1	(2,4- dihydroxy- 5- isopropylphenyl)- (5- (4- methylpiperazin- 1- ylmethyl)- 1,3- dihydroisoindol- 2- yl)methanoneIBA 12/2020
1	Sorafenib (BAY 43-9006)FDA Link 10/2020
1	Bevacizumab (Avastin)FDA Link 10/2020
1	romidepsin (FK228)FDA Link 10/2019
1	Histone Deacetylase 2IBA 10/2019
1	RNA (Ribonucleic Acid)IBA 10/2019
1	Mechanistic Target of Rapamycin Complex 1IBA 11/2018
1	Cell-Free Nucleic AcidsIBA 08/2018
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 05/2018
1	Serine (L-Serine)FDA Link 05/2018
1	Temozolomide (Temodar)FDA LinkGeneric 01/2017
1	Progesterone Receptors (Progesterone Receptor)IBA 01/2017
1	Estrogen ReceptorsIBA 01/2017
1	Cytotoxins (Cytolysins)IBA 01/2017
1	pazopanib FDA Link 01/2017
1	Everolimus FDA Link 01/2016
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2015
1	pegaspargase (Oncaspar)FDA Link 05/2013
1	Fibrinogen (Factor I)FDA Link 05/2013
1	Asparaginase (Elspar)FDA Link 05/2013
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 05/2013
1	Therapeutic UsesIBA 03/2008
1	RetinoidsIBA 03/2008

Therapy/Procedure

13	Therapeutics 01/2022 - 09/2010
6	Drug Therapy (Chemotherapy) 07/2023 - 01/2017
1	Pain Management 01/2024
1	Precision Medicine 05/2021
1	Intravenous Infusions 05/2013
1	Chemoprevention 03/2008